Article

Sexual dysfunction, Peyronie’s research centers on medical therapies

In the area of sexual dysfunction, much of the clinical research continues to focus on medical therapies, and this will be evident at the upcoming AUA annual meeting in San Diego.

This article is part of the State of Urology 2013

In the area of sexual dysfunction, much of the clinical research continues to focus on medical therapies, and this will be evident at the upcoming AUA annual meeting in San Diego. In addition, cardiovascular screening in patients presenting with erectile dysfunction remains a high-interest topic, said John J. Mulcahy, MD, PhD, a sexual medicine specialist in private practice in Madison, AL.

Dr. Mulcahy also suggests that AUA attendees watch for new research on collagenase clostridium histolyticum (XIAFLEX) as a treatment for men with Peyronie’s disease. The data are timely, as the FDA has accepted for filing the supplemental biologics license application for this agent and is expected to take action on the application by Sept. 6, 2013. Expect new research findings on priapism and its treatment, Dr. Mulcahy added.

His specific abstract recommendations are as follows:

1230: Clinical Efficacy of Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease by Baseline Penile Curvature Severity Stratum: Results from Two Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies

Larry Lipshultz

 

1656: Clinical Evaluation of Treatment of Peyronie’s Disease with Collagenase Clostridium Histolyticum: Analysis of Penile Curvature Deformity by Duration of Disease and Plaque Calcification

Irwin Goldstein

 

1658: Composite Responders Showed Improvement in Both Penile Curvature Deformity and Symptom Bother in Two Large Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies of Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease

Wayne Hellstrom

 

1660: Integrated Safety Profile of Collagenase Clostridium Histolyticum in Clinical Studies Evaluating the Treatment of Peyronie’s Disease

Culley Carson, III

 

1661: Curvature Deformity and Symptom Bother Improvement Over Time in Patients with Peyronie’s Disease Treated with Collagenase Clostridium Histolyticum

Christopher McMahon

 

1512: A Pilot Study to Determine Penile Oxygen Saturation Before and After Vacuum Therapy in Patients with Erectile Dysfunction After Radical Prostatectomy

Charles Welliver

 

1666: The “No Touch” Technique Decreases the Risk of Infection after Removal and Replacement of Malfunctioned Penile Prosthesis to 0.35%

Seth D. Cohen

 

1670: The fate of patients developing erectile dysfunction after plaque incision and grafting for Peyronie’s disease

Raanan Tal

 

 

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Elia Abou Charaweb, MD, answers a question during a video interview
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Justin Dubin, MD, answers a question during a video interview
Michael Jenson, PA-C, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.